期刊文献+

C-MYC在涎腺腺样囊性癌中的表达及意义

Expression of C-MYC in salivary adenoid cystic carcinoma and its clinicopathological significance
下载PDF
导出
摘要 目的:研究原癌基因C- MYC在涎腺腺样囊性癌(SACC)中的表达及意义。方法应用免疫组化法对54例SACC和20例正常涎腺组织石蜡标本中C- MYC表达水平进行检测并比较。结果20例正常涎腺组织中C- MYC均呈阴性表达,54例SACC标本中C- MYC阳性表达43例,阳性率为79.6%,差异有统计学意义(P<0.05)。有神经浸润、T4期C- MYC阳性率较无神经浸润、T1-3期高(P<0.05),C- MYC的表达与年龄、性别、肿瘤部位、组织学类型、远处转移及淋巴结转移等生物学特性的差异均无统计学意义(均P>0.05)。结论原癌基因C- MYC在SACC中高表达,与T分期及神经侵犯有关,有望成为SACC进展及预后的生物学标志之一。 Objective To investigate the expression of C- MYC in salivary adenoid cystic carcinoma (SACC) and clinico-pathological significance. Methods Immunohistochemisty was used to determine tissue expression of C- MYC in 54 patients with salivary adenoid cystic carcinoma from Zhejiang Provincial Cancer Hospital and 20 samples of normal gland tissue. The clin-icopathological significance of C- MYC expression was analyzed. Results C- MYC was positively expressed in 43 of 54 SACC tissues and none of 20 normal salivary gland tissues with the positive rate was 79.6%and 0.0%, respectively (P〈0.05). Further-more, C- MYC expression was higher in stage T4 and perineural invasion patients than those with state T1-3 and no perineural in-vasion patients(P〈0.05). C- MYC expression was not correlated with age, gender, tumor location, lymph node metastasis, distant metastasis and histological type (P〉0.05). Conclusion The expression of proto- oncogene C- MYC was correlated with T stag-ing and perineural invasion in SACC, incicating that it may be uses as a biological marker for SACC progress and prognosis.
出处 《浙江医学》 CAS 2014年第4期278-280,共3页 Zhejiang Medical Journal
基金 浙江省医药卫生平台重点资助计划(2012ZDA005) 浙江省卫生高层次创新人才培养工程基金资助[浙卫发2008(134)]
关键词 腺样囊性癌 涎腺肿瘤 C- MYC基因 免疫组化 Carcinoma Adenoid cystic salivary gland neoplasms C- MYC Immunohistochemistry
  • 相关文献

参考文献18

  • 1Godge P, Sharma S, Yadav M. Adenoid cystic carcinoma of the parotid gland[J]. Contemp Clin Dent, 2012, 3(2): 223-226.
  • 2Pouryazdanparast P, Brenner A, Haghighat Z, et al. The role of 8q24 copy number gains and c-MYC expression in amelanotic cutaneous melanoma[J]. Mod Pathol, 2012, 25(9): 1221-1226.
  • 3Dang C V, O'Donnell K A, Zeller K I, et al. The c-Myc target genenetwork[J]. Semin Cancer Biol, 2006, 16(4): 253-264.
  • 4Kaposi-Novak P, Libbrecht L, Woo H G, et al. Central role of c- Myc during malignant conversion in human hepatocarcinogene- sis[J]. Cancer Res, 2009, 69(7): 2775-2782.
  • 5Chen Y, Xu J, Borowicz S, et al. c-Myc activates BRCA1 gene expression through distal promoter elements in breast cancer cells[J]. BMC Cancer, 2011, 11: 246-259.
  • 6Rughooputh S, Manraj S, Eddoo R, et al. Expression of the c-myc oncogene and the presence of HPV 18: possible surrogate markers for cervical cancer[J]. Br J Biomed Sci, 2009, 66(2): 74-78.
  • 7Hawksworth D, Ravindranath L, Chert Y, et al. Overexpression of C-MYC oncogene in prostate cancer predicts biochemical re- currence[J]. Prostate Cancer Prostatic Dis, 2010, 13(4): 311-315.
  • 8Sequeiros-Santiago G, Garcia-Carracedo D, Fresno M F, et al. ~ncogene amplification pattern in adenoid cystic carcinoma of the salivary glands[J]. Oncol Rep, 2009, 21(5): 1215-1222.
  • 9Sobin L H, Gospodarowicz M K, Wittekind C. International Union Against Cancer (UICC): TNM Classification of Malignant Tumours [M]. 7th. New York: Wiley-Liss, 2010:117-126.
  • 10葛明华,凌志强,谭卓,陈超,徐加杰,余江流.表皮生长因子受体在涎腺腺样囊性癌中的表达及其在肿瘤侵袭中的作用[J].中华肿瘤杂志,2012,34(4):278-280. 被引量:4

二级参考文献17

  • 1Laurie SA,Ho AL,Fury MG. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands:a systematic review[J].Lancet Oncology,2011.815-824.doi:10.1016/S1470-2045(10)70245-X.
  • 2Banett AW,Speight PM. Perineural invasion in adenoid cystic carcinoma of the salivary glands:a valid prognostic indicator[J].Oral Oncology,2009.936-940.
  • 3Hardy S,Julien SG,Tremblay ML. Impact of oncogenic protein tyrosine phosphatases in cancer[J].Anticancer Agents Med Chem,2012.4-18.doi:10.2174/187152012798764741.
  • 4Gotoh N. Somatic mutations of the EGF receptor and their signal transducers affect the efficacy of EGF receptor-specific tyrosine kinase inhibitors[J].Int J Clin Exp Pathol,2011.403-409.
  • 5Segatto O,Anastasi S,Alema S. Regulation of epidermal growth factor receptor signalling by inducible feedback inhibitors[J].Journal of Cell Science,2011.1785-1793.doi:10.1242/jcs.083303.
  • 6Bartholomeusz C,Yamasski F,Saso H. Gemcitabine overoomes erlotinib resistance in EGFR-overexpressing cancer cells through downregulation of Akt[J].Cancer,2011.435-442.
  • 7Malapelle U,Bellevicine C,Zeppa P. Cytology-based gene mutation tests to predict response to anti-epidermal growth factor receptor therapy:a review[J].Diagnostic Cytopathology,2011.703-710.
  • 8Janku F,Garrido-Laguna I,Petruzelka LB. Novel therapeutic targets in non-small cell lung cancer[J].JOURNAL OF THORACIC ONCOLOGY,2011.1601-1612.doi:10.1097/JTO.0b013e31822944b3.
  • 9Howe LR,Brown PH. Targeting the HER/EGFR/ErbB family to prevent breast cancer[J].Cancer Prev Res (Phila),2011.1149-1157.doi:10.1158/1940-6207.CAPR-11-0334.
  • 10Naik DS,Sharma S,Ray A. Epidermal growth factor receptor expression in urinary bladder cancer[J].INDIAN JOURNAL OF UROLOGY,2011.208-214.

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部